Unlock stock picks and a broker-level newsfeed that powers Wall Street.

High Growth Tech Stocks In The US Market May 2025

In This Article:

Over the last 7 days, the United States market has risen by 2.7%, contributing to a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market trends.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.35%

33.99%

★★★★★★

Travere Therapeutics

28.65%

66.06%

★★★★★★

TG Therapeutics

26.06%

37.39%

★★★★★★

Arcutis Biotherapeutics

26.11%

58.46%

★★★★★★

Clene

62.08%

64.01%

★★★★★★

Alnylam Pharmaceuticals

23.08%

58.85%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Alkami Technology

20.71%

92.32%

★★★★★★

Ascendis Pharma

32.75%

59.64%

★★★★★★

Lumentum Holdings

21.34%

120.49%

★★★★★★

Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

BridgeBio Pharma

Simply Wall St Growth Rating: ★★★★★☆

Overview: BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, testing, and delivering transformative medicines for genetic diseases and cancers, with a market cap of approximately $7.29 billion.

Operations: BridgeBio Pharma, Inc. generates revenue primarily from identifying and advancing transformative medicines to treat patients, reporting $127.42 million in this segment. The company is focused on addressing genetic diseases and cancers through its biopharmaceutical innovations.

BridgeBio Pharma, with its robust pipeline and strategic collaborations, exemplifies innovation in the biotech sector. Despite a challenging financial position with less than one year of cash runway and ongoing unprofitability, the company's revenue is projected to grow at 42.6% annually, outpacing the US market's 8.2%. Recent approvals for its leading drug acoramidis in multiple regions underscore its potential to address significant unmet medical needs in cardiomyopathy. These developments could catalyze future profitability, as evidenced by an expected earnings growth of 62.14% per year over the next three years.

NasdaqGS:BBIO Revenue and Expenses Breakdown as at May 2025
NasdaqGS:BBIO Revenue and Expenses Breakdown as at May 2025

Kingsoft Cloud Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingsoft Cloud Holdings Limited is a company that offers cloud services to businesses and organizations mainly in China, with a market capitalization of approximately $3.42 billion.